Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology
Clinical trial NCT03366142 · COMPLETED
Trial details
- NCT number
- NCT03366142
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-02
- Primary completion
- 2024-10-16
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.